Core Viewpoint - Former hedge fund manager Martin Shkreli has warned of a potential 90% drop in shares of Inmune Bio Inc., a biotech startup focused on using the immune system to combat cancers, following a recent surge in its stock price [1][2]. Group 1: Stock Performance and Predictions - Shkreli predicts that Inmune Bio's stock could fall to $0.50, representing a 90.61% decline from its closing price of $5.33 on the previous Friday [2]. - The company's shares had recently surged by 44% due to investor enthusiasm surrounding its neuroinflammation candidate, XPro1595, which targets Alzheimer's disease and other central nervous system disorders [2]. Group 2: Critique of Inmune Bio - Shkreli has expressed concerns regarding the lack of robust Phase 1 trial data and the absence of peer-reviewed publications supporting the efficacy of the candidate [4]. - He criticized the study design for not including a placebo arm, which complicates the assessment of whether observed improvements are due to the drug or a placebo effect [4]. - BMF Reports, an activist short-seller, has echoed Shkreli's concerns, highlighting flawed science, questionable trial designs, and accounting improprieties, including payments to "ghost consultants" [5]. Group 3: Market Reaction - Following Shkreli's warning, Inmune Bio's shares fell by 15.13% on Friday and continued to decline by 16.32% in after-hours trading [7].

Company Overview - INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments targeting the innate immune system to combat diseases, particularly Alzheimer's Disease [3] - The company operates three product platforms: Dominant-Negative Tumor Necrosis Factor (DN-TNF), Natural Killer Cell Priming Platform, and CORDStrom™ [3] - DN-TNF product candidates are in clinical trials for Mild Alzheimer's disease, Mild Cognitive Impairment, and treatment-resistant depression [3] - INKmune® is designed to prime NK cells to eliminate minimal residual disease in cancer patients and is currently in trials for metastatic castration-resistant prostate cancer [3] - CORDStrom™ is a proprietary platform that recently completed a trial in recessive dystrophic epidermolysis bullosa [3] Upcoming Events - The company will host a conference call on May 8th, 2025, at 4:30 PM EDT to discuss the results for the quarter ended March 31, 2025, and provide a corporate update [1][2] - Participants can join the call by dialing in 5 to 10 minutes before the start time [2] Financial Information - The company is publicly traded on NASDAQ under the ticker INMB [3]